Loading Now

Sun Pharma’s FY25 R&D spend to fall below 7% of sales; Q3 revenue up 10.5%

Sun Pharma’s FY25 R&D spend to fall below 7% of sales; Q3 revenue up 10.5%


Sun Pharmaceutical Industries expects its total research spend to be shy of its guidance of 7 percent of sales for this financial year, top management said.

The company continues to invest in its research and development pipeline for its specialty and generics business, said Dilip Shanghvi, Sun Pharma Chairman and Managing Director.  “Because of delay in our clinical spend, our R&D (research and development) expenditure is trending below our guidance, and for the full year we now expect FY25 R&D spend to be less than 7 percent of our sales,” he told analysts after the company announced its financial performance for Q3, or three months ended December 31, 2024.

Further, he explained that finalising trial protocols took time, but the company was now in talks with clinical research organisations to accelerate the studies “by both increasing the number of study sites  as well as the number of countries in which we will do the study.”

The company’s consolidated R&D investment stood at ₹845 crore, for Q3 FY25 or 6.3 per cent of sales. Specialty R&D accounted for 41 per cent of the total R&D spend for the quarter.

Q3 results

Sun Pharma clocked a total revenue of ₹13,675 crore for Q3, which ended December 31, 2024, up 10.5 per cent from ₹12,380 crore in the same period last year. Its net profit stood at ₹2,903 crore for the period under review, up 15 per cent compared to ₹2,523 crore last year.





Source link

Post Comment